Lansoprazole (15 and 30 mg) capsules: Supply issue
Due to an issue at the factory, Lanzol Relief 15 mg capsules (Pharmacodes: 2726017 / 2482533) and 30 mg capsules (Pharmacode: 2482541) will be or are unavailable.
17 November 2026 | 15 mg now running low, new alternatives
Unfortunately, the 15 mg capsule of Lanzol Relief (Pharmacodes: 2482533 / 2726017) will now run out before the issues at the factory can be resolved. The supplier has found an alternative and it will be listed from 1 December 2026.
The temporary alternative 30 mg tablet, Lansoprazole (Viatris) ODT (Pharmacode: 2730200) is also running low. We have found another alternative. It will be listed from 1 December 2026.
Affected product
The supplier has run out of the following product:
Chemical: Lansoprazole
Brand: Lanzol Relief
Presentation: Cap 30 mg
- Pharmacode: 2482541
- Subsidy: $5.43
- Measure / Qty: per 100
Presentation: Cap 15 mg
- Pharmacode: 2482533
- Subsidy: $4.04
- Measure / Qty: per 100
- Pharmacode: 2726017
- Subsidy: $1.21
- Measure / Qty: per 30
People who take Lanzol Relief
To make sure you can still get your treatment, we have funded different brands of lansoprazole.
Lansoprazole (Viatris)
You may receive the Lansoprazole (Viatris) brand, in either the 15 mg or 30 mg strength. This brand is a tablet that dissolves on your tongue, rather than a capsule you swallow.
The tablets contain the same active ingredient, in the same amount as your usual brand, Lanzol Relief.
Chemo—France 30 mg
You may receive the Chemo-France 30 mg capsule.
New prescription may be needed
You may need to get a new prescription to get funded access to this medicine.
Viatris product contains phenylalanine
This Viatris product contains phenylalanine (a component of aspartame). If you have phenylketonuria (PKU), do not take this brand of lansoprazole.
We're sorry
We appreciate that changing products like this can be disruptive. This was the best option available to ensure you can continue to access the medicine you need.
Medicine not Medsafe reviewed
These brands have not been reviewed by Medsafe for use in New Zealand. However, they are used in other countries. Your prescriber will discuss this with you before they prescribe it. You can read more information about unapproved medicine on the Healthify website.
Information for pharmacists
1 December 2026 listing
We are listing two brands from 1 December to support this supply issue. Note the pack-size change for the 30 mg capsules. Medsafe has not had an opportunity to review either product. This means they need to be prescribed and dispensed in line with section 29A of the Medicines Act.
Note the Lansoprazole (Viatris) brand contains phenylalanine (a component of aspartame). It is not suitable for people with phenylketonuria (PKU).
Presentation: ODT 15 mg
- Brand: Lansoprazole (Viatris)
- Pharmacode: 2735180
- Subsidy: tbc
- Measure / Qty: per 100
Presentation: Cap 30 mg
- Brand: Chemo-France
- Pharmacode: 2738066
- Subsidy: TBC
- Measure / Qty: per 28
12 June 2026 listing
This product was funded from 12 June 2026. It is not Medsafe approved and will need to be prescribed and dispensed in line with section 29A of the Medicines Act.
- Presentation: Tab orodispersible 30 mg
- Brand: Lansoprazole (Viatris)
- Pharmacode: 2730200
- Subsidy: $5.43
- Measure/Qty: 100
- Section 29 and wastage apply
Downloadable flyer for patients
- Lansoprazole supply issue flyer | November 2026 [PDF 88 KB]
Prescribing and supplying an unapproved medicine
Section 29A of the Medicines Act 1981 allows for medicines that are not Medsafe approved to be prescribed and supplied to people when there is supply issue affecting the registered brand.
We know supplying an unapproved medicine is not ideal. In this case, however, this will allow people to continue to access an appropriate treatment.
We apologise for any inconvenience this causes.
What patients need to know about unapproved medicines – Healthify website(external link)
Expected resupply
We are working with Viatris to understand when Lanzol Relief capsules will be available again.
Who to contact
If you have questions about this issue, email enquiry@pharmac.govt.nz
Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.
Sign up to our email list for regular emails about supply issues and more(external link)